アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

physicians total care, inc. - carbidopa (unii: mnx7r8c5vo) (carbidopa - unii:mnx7r8c5vo), levodopa (unii: 46627o600j) (levodopa - unii:46627o600j) - carbidopa 25 mg - carbidopa and levodopa extended release tablets are indicated in the treatment of the symptoms of idiopathic parkinson’s disease (paralysis agitans), postencephalitic parkinsonism, and symptomatic parkinsonism which may follow injury to the nervous system by carbon monoxide intoxication and/or manganese intoxication. nonselective mao inhibitors are contraindicated for use with carbidopa and levodopa extended release tablets. these inhibitors must be discontinued at least two weeks prior to initiating therapy with carbidopa and levodopa extended release tablets. carbidopa and levodopa extended release tablets may be administered concomitantly with the manufacturer’s recommended dose of an mao inhibitor with selectivity for mao type b (e.g., selegiline hcl) (see precautions, drug interactions ). carbidopa and levodopa extended release tablets are contraindicated in patients with known hypersensitivity to any component of this drug and in patients with narrow-angle glaucoma. because levodopa may activ

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

mayne pharma inc. - carbidopa (unii: mnx7r8c5vo) (carbidopa anhydrous - unii:kr87b45rgh), levodopa (unii: 46627o600j) (levodopa - unii:46627o600j) - carbidopa anhydrous 25 mg - carbidopa and levodopa tablets, usp are indicated in the treatment of parkinson's disease, post-encephalitic parkinsonism, and symptomatic parkinsonism that  may follow carbon monoxide intoxication or manganese intoxication. carbidopa allows patients treated for parkinson's disease to use much lower doses of levodopa. some patients who responded poorly to levodopa have improved on carbidopa and levodopa. this is most likely due to decreased peripheral decarboxylation of levodopa caused by administration of carbidopa rather than by a primary effect of carbidopa on the nervous system. carbidopa has not been shown to enhance the intrinsic efficacy of levodopa. carbidopa may also reduce nausea and vomiting and permit more rapid titration of  levodopa. nonselective monoamine oxidase (mao) inhibitors are contraindicated for use with carbidopa and levodopa. these inhibitors must be discontinued at least two weeks prior to initiating therapy with this combination product. carbidopa and levodopa may be administered co

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

accord healthcare, inc. - carbidopa (unii: mnx7r8c5vo) (carbidopa anhydrous - unii:kr87b45rgh), levodopa (unii: 46627o600j) (levodopa - unii:46627o600j) - carbidopa anhydrous 50 mg - carbidopa and levodopa extended-release tablets are indicated in the treatment of parkinson's disease, post-encephalitic parkinsonism, and symptomatic parkinsonism that may follow carbon monoxide intoxication or manganese intoxication. nonselective monoamine oxidase (mao) inhibitors are contraindicated for use with carbidopa and levodopa extended-release. these inhibitors must be discontinued at least two weeks prior to initiating therapy with carbidopa and levodopa extended-release. carbidopa and levodopa extended-release may be administered concomitantly with the manufacturer's recommended dose of an mao inhibitor with selectivity for mao type b (e.g., selegiline hcl) (see precautions, drug interactions ). carbidopa and levodopa extended-release is contraindicated in patients with known hypersensitivity to any component of this drug, and in patients with narrow-angle glaucoma.

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

aphena pharma solutions - tennessee, llc - carbidopa (unii: mnx7r8c5vo) (carbidopa anhydrous - unii:kr87b45rgh), levodopa (unii: 46627o600j) (levodopa - unii:46627o600j) - carbidopa anhydrous 25 mg - carbidopa and levodopa tablets, usp are indicated in the treatment of parkinson's disease, post-encephalitic parkinsonism, and symptomatic parkinsonism that may follow carbon monoxide intoxication or manganese intoxication. carbidopa allows patients treated for parkinson's disease to use much lower doses of levodopa. some patients who responded poorly to levodopa have improved on carbidopa and levodopa tablets. this is most likely due to decreased peripheral decarboxylation of levodopa caused by administration of carbidopa rather than by a primary effect of carbidopa on the nervous system. carbidopa has not been shown to enhance the intrinsic efficacy of levodopa. carbidopa may also reduce nausea and vomiting and permit more rapid titration of levodopa. nonselective monoamine oxidase (mao) inhibitors are contraindicated for use with carbidopa and levodopa tablets. these inhibitors must be discontinued at least 2 weeks prior to initiating therapy with carbidopa and levodopa tablets. carbidopa and levodopa tabl

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - carbidopa monohydrate, quantity: 54.1 mg (equivalent: carbidopa, qty 50 mg); levodopa, quantity: 200 mg; entacapone, quantity: 200 mg - tablet, film coated - excipient ingredients: mannitol; titanium dioxide; sucrose; magnesium stearate; croscarmellose sodium; glycerol; povidone; iron oxide red; maize starch; hypromellose; polysorbate 80 - l.c.e. sandoz 200/50/200 is indicated for the management of patients with parkinson's disease who are experiencing motor fluctuations.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - carbidopa monohydrate, quantity: 40.5 mg (equivalent: carbidopa, qty 37.5 mg); entacapone, quantity: 200 mg; levodopa, quantity: 150 mg - tablet, film coated - excipient ingredients: iron oxide yellow; croscarmellose sodium; povidone; magnesium stearate; polysorbate 80; glycerol; sucrose; iron oxide red; hypromellose; mannitol; titanium dioxide; maize starch - l.c.e. sandoz 150/37.5/200 is indicated for the management of patients with parkinson's disease who are experiencing motor fluctuations.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - carbidopa monohydrate, quantity: 33.8 mg (equivalent: carbidopa, qty 31.25 mg); levodopa, quantity: 125 mg; entacapone, quantity: 200 mg - tablet, film coated - excipient ingredients: glycerol; titanium dioxide; croscarmellose sodium; sucrose; magnesium stearate; polysorbate 80; mannitol; maize starch; povidone; iron oxide red; hypromellose - l.c.e. sandoz 125/31.25/200 is indicated for the management of patients with parkinson's disease who are experiencing motor fluctuations.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - carbidopa monohydrate, quantity: 27 mg (equivalent: carbidopa, qty 25 mg); levodopa, quantity: 100 mg; entacapone, quantity: 200 mg - tablet, film coated - excipient ingredients: povidone; iron oxide yellow; croscarmellose sodium; mannitol; glycerol; maize starch; titanium dioxide; magnesium stearate; polysorbate 80; hypromellose; sucrose; iron oxide red - l.c.e. sandoz 100/25/200 is indicated for the management of patients with parkinson's disease who are experiencing motor fluctuations.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - carbidopa monohydrate, quantity: 20.25 mg (equivalent: carbidopa, qty 18.75 mg); entacapone, quantity: 200 mg; levodopa, quantity: 75 mg - tablet, film coated - excipient ingredients: polysorbate 80; maize starch; hypromellose; croscarmellose sodium; iron oxide red; titanium dioxide; povidone; magnesium stearate; glycerol; mannitol; sucrose - l.c.e. sandoz 75/18.75/200 is indicated for the management of patients with parkinson's disease who are experiencing motor fluctuations.

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

mylan pharmaceuticals inc. - carbidopa (unii: mnx7r8c5vo) (carbidopa anhydrous - unii:kr87b45rgh), levodopa (unii: 46627o600j) (levodopa - unii:46627o600j), entacapone (unii: 4975g9nm6t) (entacapone - unii:4975g9nm6t) - carbidopa anhydrous 12.5 mg - carbidopa, levodopa and entacapone tablets, a combination drug consisting of levodopa, carbidopa (dopa decarboxylase inhibitor), and entacapone (catechol-o-methyltransferase-comt inhibitor) is indicated for the treatment of parkinson’s disease. carbidopa, levodopa and entacapone tablets can be used: carbidopa, levodopa and entacapone tablets are contraindicated in patients: there are no adequate and well-controlled studies in pregnant women. it has been reported from individual cases that levodopa crosses the human placental barrier, enters the fetus, and is metabolized. in animals, administration of carbidopa-levodopa or entacapone during pregnancy was associated with developmental toxicity, including increased incidences of fetal malformations. carbidopa, levodopa and entacapone tablets should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. in nonclinical studies in which carbidopa-levodopa was administered to pregnant animals, increased incidences of viscer